RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Raises Price Target to $1240
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1232 to $1240.
August 02, 2024 | 8:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams maintains an Outperform rating on Regeneron Pharmaceuticals and raises the price target from $1232 to $1240.
The raised price target and maintained Outperform rating from a reputable analyst at RBC Capital is likely to positively impact Regeneron's stock price in the short term. Investors often view such updates as a sign of confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100